scholarly journals The Challenges of Diagnostic and Management of Acute Heart Failure From Hemodynamic Subset to Appropriate Treatment

2017 ◽  
Vol 3 (2) ◽  
pp. 14
Author(s):  
I Gede Sumantra
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Medical Problem ◽  
Morbidity And Mortality ◽  
Major Morbidity ◽  
Management Evaluation ◽  
Appropriate Treatment ◽  
Universal Definition ◽  
Definition Of ◽  
Based Medicine

Acute heart failure (AHF) is a common and growing medical problem associated with major morbidity and mortality. Despite the high prevalence of this condition and its associated major morbidity and mortality, diagnosis can be difficult, and optimal treatment remains poorly defined. Identification of the acute triggers for the decompensation as well as characterization of cardiac filling pressures and output is central to management. Evaluation of patients with Heart Failure (HF) is critical for the appropriate selection and monitoring of therapy as well as for the prevention of recurrent hospitalizations.Diagnostic and management AHF is a challenge because of the heterogeneity of the patient population, the existence of a universal definition of understanding, not understanding the pathophysiology, and the lack of bases guideline Evidence-based medicine

scholarly journals Clinical and etiological profile of acute heart failure: an observational study

2020 ◽  
Vol 7 (3) ◽  
pp. 502
Author(s):  
Kiran Teja Varigonda ◽  
Khamitkar Shankar Rao Subramani ◽  
C. N. Manjunath
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Medical Problem ◽  
Response To Treatment ◽  
Heart Failure Treatment ◽  
Cardiac Symptom ◽  
Major Morbidity ◽  
Institutional Ethics ◽  
Supportive Management ◽  
Indian Data

Background: Acute heart failure (AHF) is a common and growing medical problem associated with major morbidity and mortality. It is the leading reason for hospital admission among patients over age 65 years. Not much of data is available from India, there are a lot of differences between the western data and available Indian data. Prompt diagnosis, identification of reversible causes and supportive management in ICU is of paramount importance.Methods: This study was conducted at Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka after the institutional ethics committee approval. Those patients who were diagnosed to have AHF, were evaluated and treated as per the institution protocols in ICU and standard medical care which includes diuretics, inotropes and vasopressors. All the patients were prospectively studied; investigated for the etiology of AHF.Results: Majority of patients presenting as Acute Heart Failure are of 60 years mean age, with 63% males. Ischemic heart disease is the leading cause of Acute Heart Failure. Shortness of breath was the commonest presentation followed by crackles. Abdominal pain was the most common (28%) non cardiac symptom. There is no significant correlation between the presence of anemia and mortality. Hyponatremia had relation with mortality. 22% had HFpEF, rest had HFrEF. The mean hospital stay was 8.3 days. The study mortality was 9 % and the 30-day mortality was 13 % in our study.Conclusions: Current available data from Indian studies and registries has a lot of difference from the western data with regards to causes, response to treatment, and more such data is needed to frame regional guidelines for better understanding of presentation of heart failure ,treatment and risk factors for mortality.

Biomarkers in acute heart failure

2015 ◽  
Author(s):  
Rajiv Choudhary ◽  
Kevin Shah ◽  
Alan Maisel
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Natriuretic Peptides ◽  
Health Care Systems ◽  
Medical Problem ◽  
National Health Care ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Acute Dyspnoea ◽  
Care Systems ◽  
Neutrophil Gelatinase

Acute heart failure continues to be a worldwide medical problem, associated with frequent readmissions, high mortality, and a profound economic impact on national health care systems. In the past decade, biomarkers have shifted the way in which acute heart failure is managed by the cardiologist. The search for the ideal biomarker to aid in the diagnosis, prognosis, and treatment of acute heart failure is ongoing. The natriuretic peptides have proved extremely useful in determining whether acute dyspnoea has a cardiac aetiology. In addition, recent trials have demonstrated the use of natriuretic peptides in inpatient and outpatient prognosis, as well as in titrating medications in outpatients with chronic heart failure to prevent acute heart failure hospitalizations. Other emerging acute heart failure biomarkers include mid-regional pro-adrenomedullin, mid-regional proatrial natriuretic peptide, troponin, ST2, and neutrophil gelatinase-associated lipocalin.

Biomarkers in acute heart failure

2018 ◽  
Author(s):  
Rajiv Choudhary ◽  
Kevin Shah ◽  
Alan Maisel
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Health Care Systems ◽  
Medical Problem ◽  
National Health Care ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Acute Dyspnoea ◽  
Care Systems ◽  
Neutrophil Gelatinase ◽  
The Ideal

Acute heart failure continues to be a worldwide medical problem, associated with frequent readmissions, high mortality, and a profound economic impact on national health care systems. In the past decade, biomarkers have shifted the way in which acute heart failure is managed by the cardiologist. The search for the ideal biomarker to aid in the diagnosis, prognosis, and treatment of acute heart failure is ongoing. The natriureticfc peptides have proved extremely useful in determining whether acute dyspnoea has a cardiac aetiology. In addition, recent trials have demonstrated the use of natriuretic peptides in inpatient and outpatient prognosis, as well as in titrating medications in outpatients with chronic heart failure to prevent acute heart failure hospitalizations. Other emerging acute heart failure biomarkers include mid-regional pro-adrenomedullin, mid-regional proatrial natriuretic peptide, troponin, ST2, and neutrophil gelatinase-associated lipocalin.

Biomarkers in acute heart failure

2021 ◽  
pp. 409-424
Author(s):  
Rajiv Choudhary ◽  
Nicholas Wettersten ◽  
Kevin Shah ◽  
Alan Maisel
Keyword(s):  
Heart Failure ◽  
Health Care ◽  
Acute Heart Failure ◽  
Health Care Systems ◽  
High Sensitivity ◽  
Medical Problem ◽  
National Health Care ◽  
Acute Dyspnoea ◽  
Galectin 3 ◽  
Care Systems

Acute heart failure continues to be a worldwide medical problem, associated with frequent readmissions, high mortality, and a profound economic impact on national health care systems. Biomarkers have shifted the way in which acute heart failure is managed by the cardiologist. The search for the ideal biomarker to aid in the diagnosis, prognosis, and treatment of acute heart failure is ongoing. The natriuretic peptides have come close to an ideal biomarker and prove extremely useful in determining whether acute dyspnoea has a cardiac aetiology. Furthermore, they are useful for prognosis and may have a role in guiding management of heart failure. Additionally, high-sensitivity troponin, sST2, and galectin-3 are increasingly used with mounting clinical evidence for utility. Other emerging acute heart failure biomarkers include mid-regional pro-adrenomedullin, bio-adrenomedulin, mid-regional proatrial natriuretic peptide, and procalcitonin.

Sign in / Sign up

Export Citation Format

Share Document